Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02499159 · ClinicalTrials.gov registry record · Phase 4
Pain Management in Response to Exparel vs. Standard Bupivicaine
A Phase 4 study, sponsored by Inova Health Care Services.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT02499159 is a Phase 4 study that has completed, run by Inova Health Care Services. The registered enrollment target is 100 participants.
The verdict
NCT02499159, a Phase 4 study, has completed, sponsored by Inova Health Care Services.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study is looking to evaluate the efficacy of liposomal bupivicaine (Exparel) on decreasing the amount of consumed pain medications. Patients will be randomly selected to received either Exparel or standard bupivicaine injection during surgery. Patients will be followed up to assess pain levels using a visual pain scale, and to assess how much pain medication was consumed.
Interventions
- DRUG Liposomal Bupivicaine
- DRUG 0.25% standard bupivicaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02499159
The ClinicalTrials.gov registry entry for NCT02499159 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal Bupivicaine is the first listed.
NCT02499159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02499159 about?
NCT02499159 is a clinical study titled "Pain Management in Response to Exparel vs. Standard Bupivicaine". This study is looking to evaluate the efficacy of liposomal bupivicaine (Exparel) on decreasing the amount of consumed pain medications. Patients will be randomly selected to received either Exparel or standard bupivicaine injection during surgery. Patients will be followed up to assess pain levels...
What is the current status of trial NCT02499159?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2014-12. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02499159?
The interventions under investigation include: Liposomal Bupivicaine (DRUG), 0.25% standard bupivicaine (DRUG).
Who is sponsoring clinical trial NCT02499159?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.